Enabling fast and appropriate drug product supply for phase 1 clinical trials


Reducing the timeline from conception to Phase 1 trials can be especially challenging for new and emerging biotechs. Since many of them are completely virtual or have limited lab space capabilities, they often do not have in-house resources and capacity for formulation development. Without the ability to move smoothly from lab concept to the manufacture and delivery of GMP clinical supplies to patients, critical milestones could be missed, potentially delaying funding commitments from investors.

Download this white paper to learn more about:

  • Securing the future of your molecule
  • Strategies to lay the foundation for commercial success
  • Case studies